Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas

被引:100
作者
Milde-Langosch, K [1 ]
Riethdorf, S
Kraus-Pöppinghaus, A
Riethdorf, L
Löning, T
机构
[1] Univ Hamburg, Hosp Eppendorf, Dept Gynecopathol, Inst Pathol, Hamburg, Germany
[2] Univ Hamburg, Krankenhaus Eppendorf, Inst Pathol, D-20246 Hamburg, Germany
关键词
cervical adenocarcinoma; HPV; p16; p21; p27;
D O I
10.1007/s004280100439
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Inactivation or down-regulation of the cell-cycle inhibitors p16(MTS1), p21(WAF1), and p27(KIP1) is involved in the carcinogenesis of various human tumors. In cervical squamous cell carcinomas that are associated with human papillomavirus (HPV) infection, the expression or function of these proteins is impaired by the action of viral oncoproteins E6 and E7. Comparably less is known about the role of these cyclin-dependent kinase inhibitors in cervical adenocarcinomas, 15-40% of which are HPV negative. Therefore, we studied the expression of p16(MTS1), p21(WAF1), and p27(KIP1) by immunohistochemistry in 60 cervical adenocarcinomas. HPV infection was determined by PCR, and HPV 16 and 18 E6/E7 oncogene expression was analyzed by RNA-RNA in situ hybridization. We found significant correlations of strong p16 expression with HPV 16/18 infection and HPV 16/18 E6/E7 oncogene expression (P=0.001). Moderate or strong p16 expression was also observed in 41% of HPV-negative carcinomas, indicating that HPV-independent mechanisms might also lead to p16 overexpression. In addition, stronger p2l and p27 expression was significantly associated with the detection of HPV 16 or 18 E6/E7 transcripts (P=0.015 and 0.030, respectively). Obviously, the tumor suppressor action of these proteins can be overcome in HPV-positive lesions. In contrast, absent or low p16, p21, and p27 immunostaining was observed in most HPV-negative cervical adenocarcinomas and might contribute to carcinogenesis in these tumors.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 43 条
[1]   PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].
BOSCH, FX ;
MANOS, MM ;
MUNOZ, N ;
SHERMAN, M ;
JANSEN, AM ;
PETO, J ;
SCHIFFMAN, MH ;
MORENO, V ;
KURMAN, R ;
SHAH, KV ;
ALIHONOU, E ;
BAYO, S ;
MOKHTAR, HC ;
CHICAREON, S ;
DAUDT, A ;
DELOSRIOS, E ;
GHADIRIAN, P ;
KITINYA, JN ;
KOULIBALY, M ;
NGELANGEL, C ;
TINTORE, LMP ;
RIOSDALENZ, JL ;
SARJADI ;
SCHNEIDER, A ;
TAFUR, L ;
TEYSSIE, AR ;
ROLON, PA ;
TORROELLA, M ;
TAPIA, AV ;
WABINGA, HR ;
ZATONSKI, W ;
SYLLA, B ;
VIZCAINO, P ;
MAGNIN, D ;
KALDOR, J ;
GREER, C ;
WHEELER, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802
[2]  
Caffo O, 1996, CLIN CANCER RES, V2, P1591
[3]   Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer [J].
Catzavelos, C ;
Bhatacharya, N ;
Ung, YC ;
Wilson, JA ;
Roncari, L ;
Sandhu, C ;
Shaw, P ;
Yeger, H ;
MoravaProtzner, I ;
Kapusta, L ;
Franssen, E ;
Pritchard, KI ;
Slingerland, JM .
NATURE MEDICINE, 1997, 3 (02) :227-230
[4]  
CHEN YQ, 1995, CANCER RES, V55, P4536
[5]   CELL-CYCLE AND CANCER [J].
CLURMAN, BE ;
ROBERTS, JM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (20) :1499-1501
[6]   THE HUMAN PAPILLOMAVIRUS STATUS OF INVASIVE CERVICAL ADENOCARCINOMA - A CLINICOPATHOLOGICAL AND OUTCOME ANALYSIS [J].
DUGGAN, MA ;
MCGREGOR, SE ;
BENOIT, JL ;
INOUE, M ;
NATION, JG ;
STUART, GCE .
HUMAN PATHOLOGY, 1995, 26 (03) :319-325
[7]   HUMAN PAPILLOMAVIRUS TYPE-16 (HPV-16) GENE-EXPRESSION AND DNA-REPLICATION IN CERVICAL NEOPLASIA - ANALYSIS BY INSITU HYBRIDIZATION [J].
DURST, M ;
GLITZ, D ;
SCHNEIDER, A ;
ZURHAUSEN, H .
VIROLOGY, 1992, 189 (01) :132-140
[8]  
ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301
[9]   A question of balance: The role of cyclin-kinase inhibitors in development and tumorigenesis [J].
Elledge, SJ ;
Winston, J ;
Harper, JW .
TRENDS IN CELL BIOLOGY, 1996, 6 (10) :388-392
[10]  
HOPKINS MP, 1991, OBSTET GYNECOL, V77, P912